State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
PLoS One. 2013 Apr 10;8(4):e61056. doi: 10.1371/journal.pone.0061056. Print 2013.
Hepatocellular carcinoma (HCC) is a prevalent disease worldwide, and the majority of HCC-related deaths occur due to local invasion and distant metastasis. Cancer stem cells (CSCs) are a small subpopulation of cancer cells that have been hypothesized to be responsible for metastatic disease. Recently, we and others have identified a CSC population from human HCC cell lines and xenograft tumors characterized by their expression of CD133. However, the precise molecular mechanisms by which CD133(+) cancer stem-like cells mediate HCC metastasis have not been sufficiently analyzed. Here, we have sorted HCC cells using CD133 as a cancer stem cell (CSC) marker by magnetic-activated cell sorting (MACS) and demonstrated that the CD133(+) HCC cells not only possess greater migratory and invasive capacity in vitro but are also endowed with enhanced metastatic capacity in vivo and in human HCC specimens when compared to CD133(-) HCC cells. Gene expression analysis of the CD133(+) and CD133(-) cells of the HCC line SMMC-7721 revealed that G protein-coupled receptor 87 (GPR87) is highly expressed in CD133(+) HCC cells. In this study, we explored the role of GPR87 in the regulation of CD133 expression. We demonstrated that the overexpression of GPR87 up-regulated CD133 expression, promoted CSC-associated migratory and invasive properties in vitro, and increased tumor initiation in vivo. Conversely, silencing of GPR87 expression reduced the levels of CD133 expression.
GPR87 promotes the growth and metastasis of CD133(+) cancer stem-like cells, and our findings may reveal new targets for HCC prevention or therapy.
肝细胞癌(HCC)是一种全球流行的疾病,大多数 HCC 相关死亡是由于局部侵袭和远处转移。癌症干细胞(CSC)是一小部分癌细胞,被认为是导致转移性疾病的原因。最近,我们和其他人从人 HCC 细胞系和异种移植肿瘤中鉴定出了一个 CSC 群体,其特征是表达 CD133。然而,CD133(+)癌干细胞样细胞介导 HCC 转移的确切分子机制尚未得到充分分析。在这里,我们通过磁激活细胞分选(MACS)使用 CD133 作为癌症干细胞(CSC)标志物对 HCC 细胞进行分选,并证明 CD133(+)HCC 细胞不仅在体外具有更大的迁移和侵袭能力,而且与 CD133(-)HCC 细胞相比,在体内和人 HCC 标本中具有增强的转移能力。对 HCC 细胞系 SMMC-7721 的 CD133(+)和 CD133(-)细胞的基因表达分析表明,G 蛋白偶联受体 87(GPR87)在 CD133(+)HCC 细胞中高度表达。在这项研究中,我们探讨了 GPR87 在调节 CD133 表达中的作用。我们证明,GPR87 的过表达上调了 CD133 的表达,促进了体外 CSC 相关的迁移和侵袭特性,并增加了体内肿瘤的起始。相反,沉默 GPR87 的表达降低了 CD133 的表达水平。
GPR87 促进 CD133(+)癌干细胞样细胞的生长和转移,我们的研究结果可能揭示 HCC 预防或治疗的新靶点。